

## **REFERENCES**

1. Agrawal K, Esmail AA, Gnanasegaran G, Navalkissoor S, Mittal BR, Fogelman I. Pitfalls and Limitations of Radionuclide Imaging in Endocrinology. *Semin Nucl Med.* 2015;45:440-457.
2. Al-Nahhas A, Win Z, Szyszko T, et al. Gallium-68 PET: a new frontier in receptor cancer imaging. *Anticancer Res.* 2007;27:4087-4094.
3. Alonso O, Rodriguez-Taroco M, Savio E, Bentancourt C, Gambini JP, Engler H. (68)Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin. *Ann Nucl Med.* 2014;28:638-645.
4. Amal G, Sara T, Ghofrane CS, et al. [Cutaneous Merkel cell carcinoma: role of 18FDG PET-CT]. *Pan Afr Med J.* 2016;23:156.
5. Ambrosini V, Campana D, Bodei L, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. *J Nucl Med.* 2010;51:669-673.
6. Ambrosini V, Campana D, Polverari G, et al. Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas. *J Nucl Med.* 2015;56:1843-1848.
7. Ambrosini V, Castellucci P, Rubello D, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. *Nucl Med Commun.* 2009;30:281-286.
8. Ambrosini V, Nanni C, Zompatori M, et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. *Eur J Nucl Med Mol Imaging.* 2010;37:722-727.
9. Ambrosini V, Tomassetti P, Rubello D, et al. Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours. *Nucl Med Commun.* 2007;28:473-477.
10. Ameri P, Gatto F, Arvigo M, et al. Somatostatin receptor scintigraphy in thoracic diseases. *J Endocrinol Invest.* 2007;30:889-902.
11. Arora S, Soundararajan R, Joshi P, Kumar R, Bal C. Somatostatin receptor expressing bilateral ovarian metastases detected by (68)Ga DOTANOC PET/CT. *Clin Nucl Med.* 2015;40:496-498.
12. Balogova S, Talbot JN, Nataf V, et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. *Eur J Nucl Med Mol Imaging.* 2013;40:943-966.

13. Barollo S, Bertazza L, Watutantrige-Fernando S, et al. Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors. *PLoS One*. 2016;11:e0156044.
14. Basu B, Basu S. Correlating and Combining Genomic and Proteomic Assessment with In Vivo Molecular Functional Imaging: Will This Be the Future Roadmap for Personalized Cancer Management? *Cancer Biother Radiopharm*. 2016;31:75-84.
15. Basu S, Kumar R, Rubello D, Fanti S, Alavi A. PET imaging in neuroendocrine tumors: current status and future prospects. *Minerva Endocrinol*. 2008;33:257-275.
16. Basu S, Ranade R, Ostwal V, Shrikhande SV. PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors. *PET Clin*. 2016;11:233-241.
17. Baum RP, Kulkarni HR. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience. *Theranostics*. 2012;2:437-447.
18. Baumann T, Rottenburger C, Nicolas G, Wild D. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging. *Best Pract Res Clin Endocrinol Metab*. 2016;30:45-57.
19. Belhocine T, Pierard GE, Fruhling J, et al. Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma. *Oncol Rep*. 2006;16:347-352.
20. Berardi R, Torniai M, Savini A, Rinaldi S, Cascinu S. Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? *World J Clin Oncol*. 2016;7:131-134.
21. Bergner CG, Lang C, Spreer A, Bahr M, Mohr A, Simons M. Teaching NeuroImages: Ma2 encephalitis presenting as acute panhypopituitarism in a young man. *Neurology*. 2013;81:e146-147.
22. Biermann M, Johnsen B, Sorbye H, Folling M, Sundin A, Bach-Gansmo T. [Positron emission tomography in neuroendocrine tumours]. *Tidsskr Nor Laegeforen*. 2009;129:1474-1477.
23. Blazek M, Hajek M, Novotny J. [The commonest neuroendocrine GIT tumors--carcinoids]. *Rozhl Chir*. 2007;86:652-656.
24. Bodei L, Kidd M, Modlin IM, et al. Gene transcript analysis blood values correlate with (6)(8)Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. *Eur J Nucl Med Mol Imaging*. 2015;42:1341-1352.

25. Bombardieri E, Maccauro M, Castellani MR, et al. [Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?]. *Minerva Endocrinol.* 2001;26:197-213.
26. Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. *Ann Oncol.* 2001;12 Suppl 2:S51-61.
27. Bombardieri E, Seregini E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. *Q J Nucl Med Mol Imaging.* 2004;48:150-163.
28. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. *Eur J Nucl Med Mol Imaging.* 2007;34:1617-1626.
29. Byrne KP. Metabolic epidermal necrosis-hepatocutaneous syndrome. *Vet Clin North Am Small Anim Pract.* 1999;29:1337-1355.
30. Cazzato RL, Garnon J, Ramamurthy N, et al. 18F-FDOPA PET/CT-Guided Radiofrequency Ablation of Liver Metastases from Neuroendocrine Tumours: Technical Note on a Preliminary Experience. *Cardiovasc Intervent Radiol.* 2016.
31. Chondrogiannis S, Grassetto G, Marzola MC, et al. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. *Nucl Med Commun.* 2012;33:179-184.
32. Chondrogiannis S, Marzola MC, Al-Nahhas A, et al. Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. *Nucl Med Commun.* 2013;34:1141-1149.
33. Constantinidou A, Hofman M, O'Doherty M, Acland KM, Healy C, Harries M. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. *Melanoma Res.* 2008;18:56-60.
34. Cuccurullo V, Faggiano A, Scialpi M, et al. Questions and answers: what can be said by diagnostic imaging in neuroendocrine tumors? *Minerva Endocrinol.* 2012;37:367-377.
35. Danthala M, Kallur KG, Prashant GR, Rajkumar K, Raghavendra Rao M. (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years' experience from a tertiary cancer care centre in India. *Eur J Nucl Med Mol Imaging.* 2014;41:1319-1326.
36. Delorme S, Raue F. Medullary Thyroid Carcinoma: Imaging. *Recent Results Cancer Res.* 2015;204:91-116.

- 37.** Deppen SA, Blume J, Bobbey AJ, et al. 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. *J Nucl Med.* 2016;57:872-878.
- 38.** Deppen SA, Liu E, Blume JD, et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. *J Nucl Med.* 2016;57:708-714.
- 39.** Desai K, Watkins J, Woodward N, et al. Use of molecular imaging to differentiate liver metastasis of colorectal cancer metastasis from neuroendocrine tumor origin. *J Clin Gastroenterol.* 2011;45:e8-11.
- 40.** Diez M, Teule A, Salazar R. Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment. *Ann Gastroenterol.* 2013;26:29-36.
- 41.** Doi M, Sugiyama T, Izumiyama H, Yoshimoto T, Hirata Y. Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. *Endocr J.* 2010;57:1061-1069.
- 42.** Dubash SR, Keat N, Mapelli P, et al. Clinical Translation of a 'Click' Labeled 18F-Octreotate Radioligand for Imaging Neuroendocrine Tumors. *J Nucl Med.* 2016.
- 43.** Eriksson O, Velikyan I, Selvaraju RK, et al. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. *J Clin Endocrinol Metab.* 2014;99:1519-1524.
- 44.** Ezuddin S, Fragkaki C. MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy. *Clin Nucl Med.* 2005;30:579-581.
- 45.** Fanti S, Ambrosini V, Tomassetti P, et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. *Biomed Pharmacother.* 2008;62:667-671.
- 46.** Foley KG, Fielding P, Lewis WG, et al. Prognostic significance of novel (1)(8)F-FDG PET/CT defined tumour variables in patients with oesophageal cancer. *Eur J Radiol.* 2014;83:1069-1073.
- 47.** Forrester SD, Towell TL. Feline idiopathic cystitis. *Vet Clin North Am Small Anim Pract.* 2015;45:783-806.
- 48.** Frilling A, Sotiropoulos GC, Radtke A, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. *Ann Surg.* 2010;252:850-856.

49. Froeling V, Elgeti F, Maurer MH, et al. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. *Ann Nucl Med*. 2012;26:738-743.
50. Froidevaux S, Eberle AN, Christe M, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. *Int J Cancer*. 2002;98:930-937.
51. Fuccio C, Spinapolice EG, Chondrogiannis S, et al. Evolving role of SPECT/CT in neuroendocrine tumors management: staging, treatment response, and follow-up. *Clin Nucl Med*. 2013;38:e384-389.
52. Garcheva M, Zlatareva D, Gocheva L. Positron emission tomography combined with computed tomography for diagnosis of synchronous tumors. *Klin Onkol*. 2014;27:283-286.
53. George A, Girault S, Testard A, et al. The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution. *Nucl Med Commun*. 2014;35:282-290.
54. Goldsmith SJ, Kostakoglu LA, Somrov S, Palestro CJ. Radionuclide imaging of thoracic malignancies. *Thorac Surg Clin*. 2004;14:95-112.
55. Goncalves TD, Toledo RA, Sekiya T, et al. Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life. *J Clin Endocrinol Metab*. 2014;99:E89-96.
56. Gotthardt M, Behe MP, Beuter D, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. *Eur J Nucl Med Mol Imaging*. 2006;33:1273-1279.
57. Gottwald T, Koveker G, Busing M, Lauchart W, Becker HD. Diagnosis and management of metastatic gastrinoma by multimodality treatment including liver transplantation: report of a case. *Surg Today*. 1998;28:551-558.
58. Gouffon M, Iff S, Ziegler K, et al. Diagnosis and workup of 522 consecutive patients with neuroendocrine neoplasms in Switzerland. *Swiss Med Wkly*. 2014;144:w13924.
59. Has Simsek D, Kuyumcu S, Turkmen C, et al. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? *J Nucl Med*. 2014;55:1811-1817.
60. Haug AR, Bartenstein P. [Gastroenteropancreatic neuroendocrine tumors: diagnosis and therapy in nuclear medicine]. *Internist (Berl)*. 2012;53:161-166.

- 61.** Hawryluk EB, O'Regan KN, Sheehy N, et al. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. *J Am Acad Dermatol*. 2013;68:592-599.
- 62.** Herrmann K, Czernin J, Wolin EM, et al. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective. *J Nucl Med*. 2015;56:70-75.
- 63.** Ho CL. Clinical PET imaging--an Asian perspective. *Ann Acad Med Singapore*. 2004;33:155-165.
- 64.** Hodolic M, Fettich J, Banti E, Chondrogiannis S, Al-Nahhas A, Rubello D. Diagnostics of neuroendocrine tumours. *In Vivo*. 2010;24:771-774.
- 65.** Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. *J Med Imaging Radiat Oncol*. 2012;56:40-47.
- 66.** Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. *Radiographics*. 2015;35:500-516.
- 67.** Hommann M, Kaemmerer D, Horsch D, Kulkarni HR, Robiller F, Baum RP. [The relevance of PET/CT for the surgical management of neuroendocrine neoplasms]. *Chirurg*. 2014;85:500-504.
- 68.** Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other neuroendocrine tumors. *Semin Nucl Med*. 2007;37:286-302.
- 69.** Hrehoret D, Alexandrescu S, Brasoveanu V, Grigorie R, Zielinski C, Popescu I. Liver transplantation in a patient with unresectable colorectal liver metastases -- a case report. *Chirurgia (Bucur)*. 2013;108:719-724.
- 70.** Ilhan H, Fendler WP, Cyran CC, et al. Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. *Ann Surg Oncol*. 2015;22:164-171.
- 71.** Ilias I, Pacak K. Diagnosis and management of tumors of the adrenal medulla. *Horm Metab Res*. 2005;37:717-721.
- 72.** Ingui CJ, Shah NP, Oates ME. Endocrine neoplasm scintigraphy: added value of fusing SPECT/CT images compared with traditional side-by-side analysis. *Clin Nucl Med*. 2006;31:665-672.

- 73.** Ito T, Jensen RT. Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies. *Int J Endocr Oncol.* 2016;3:53-66.
- 74.** Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY. 6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. *J Nucl Med.* 2008;49:573-586.
- 75.** Jani N, Khalid A, Kaushik N, et al. EUS-guided FNA diagnosis of pancreatic endocrine tumors: new trends identified. *Gastrointest Endosc.* 2008;67:44-50.
- 76.** Jani N, Moser AJ, Khalid A. Pancreatic endocrine tumors. *Gastroenterol Clin North Am.* 2007;36:431-439, x-xi.
- 77.** Jann H, Wertenbruch T, Pape U, et al. A matter of the heart: myocardial metastases in neuroendocrine tumors. *Horm Metab Res.* 2010;42:967-976.
- 78.** Kaemmerer D, Posorski N, Hommann M, Baum RP, Horsch D. [Hereditary syndromes of neuroendocrine tumours]. *Zentralbl Chir.* 2014;139:415-427.
- 79.** Kaemmerer D, Prasad V, Daffner W, et al. Radioguided surgery in neuroendocrine tumors using Ga-68-labeled somatostatin analogs: a pilot study. *Clin Nucl Med.* 2012;37:142-147.
- 80.** Kakade HR, Kasaliwal R, Jagtap VS, et al. Ectopic ACTH-secreting syndrome: a single-center experience. *Endocr Pract.* 2013;19:1007-1014.
- 81.** Kannivelu A, Loke KS, Kok TY, et al. The role of PET/CT in the evaluation of skeletal metastases. *Semin Musculoskelet Radiol.* 2014;18:149-165.
- 82.** Karageorgiadis AS, Papadakis GZ, Biro J, et al. Ectopic adrenocorticotrophic hormone and corticotropin-releasing hormone co-secreting tumors in children and adolescents causing cushing syndrome: a diagnostic dilemma and how to solve it. *J Clin Endocrinol Metab.* 2015;100:141-148.
- 83.** Kauhanen SP, Komar G, Seppanen MP, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. *Ann Surg.* 2009;250:957-963.
- 84.** Khan MU, Khan S, El-Refaie S, Win Z, Rubello D, Al-Nahhas A. Clinical indications for Gallium-68 positron emission tomography imaging. *Eur J Surg Oncol.* 2009;35:561-567.
- 85.** Khan MU, Morse M, Coleman RE. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. *Q J Nucl Med Mol Imaging.* 2008;52:441-454.

- 86.** Khan S, Lloyd C, Szyszko T, Win Z, Rubello D, Al-Nahhas A. PET imaging in endocrine tumours. *Minerva Endocrinol.* 2008;33:41-52.
- 87.** Kinnard MF, Alavi A, Rubin RA, Lichtenstein GR. Nuclear imaging of solid hepatic masses. *Semin Roentgenol.* 1995;30:375-395.
- 88.** Kjaer A, Knigge U. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. *Scand J Gastroenterol.* 2015;50:740-747.
- 89.** Kontis E, Vezakis A, Pantiora E, et al. Merkel cell carcinoma of unknown primary site; case presentation and review of the literature. *Ann Med Surg (Lond).* 2015;4:434-437.
- 90.** Koornstra JJ, de Vries EG, Porte RJ. Improvements in small bowel carcinoid diagnosis and staging: 18F-DOPA PET, capsule endoscopy and double balloon enteroscopy. *Dig Liver Dis.* 2009;41:e35-38.
- 91.** Krausz Y, Freedman N, Rubinstein R, et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with (1)(1)(1)In-DTPA-octreotide (OctreoScan(R)). *Mol Imaging Biol.* 2011;13:583-593.
- 92.** Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. *Endocr Relat Cancer.* 2010;17:R53-73.
- 93.** Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. *Semin Nucl Med.* 2006;36:73-92.
- 94.** Laroia ST, Sasturkar S, Rastogi A, Pamecha V. Solitary hypervascular liver metastasis from neuroendocrine tumor mimicking hepatocellular cancer: All that glitters is not gold. *Indian J Nucl Med.* 2015;30:42-46.
- 95.** Lau WY, Teoh YL, Win KM, et al. Current role of selective internal radiation with yttrium-90 in liver tumors. *Future Oncol.* 2016;12:1193-1204.
- 96.** Law WP, Fiumara F, Fong W, Macfarlane DJ. The 'double pituitary hot spot' sign of skull base meningioma on gallium-68-labelled somatostatin analogue PET. *J Med Imaging Radiat Oncol.* 2013;57:680-683.
- 97.** Le Rest C, Bomanji JB, Costa DC, Townsend CE, Visvikis D, Ell PJ. Functional imaging of malignant paragangliomas and carcinoid tumours. *Eur J Nucl Med.* 2001;28:478-482.



- 98.** Leyton J, Iddon L, Perumal M, et al. Targeting somatostatin receptors: preclinical evaluation of novel 18F-fluoroethyltriazole-Tyr3-octreotate analogs for PET. *J Nucl Med.* 2011;52:1441-1448.
- 99.** Liu EH, Solorzano CC, Katznelson L, et al. Aace/Ace disease state clinical review: diagnosis and management of midgut carcinoids. *Endocr Pract.* 2015;21:534-545.
- 100.** Lopci E, Nanni C, Rampin L, Rubello D, Fanti S. Clinical applications of 68Ga-DOTANOC in neuroendocrine tumours. *Minerva Endocrinol.* 2008;33:277-281.
- 101.** Lu SJ, Gnanasegaran G, Buscombe J, Navalkisoor S. Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature. *Nucl Med Commun.* 2013;34:98-107.
- 102.** Luo G, Liu Z, Guo M, et al. (18)F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. *Int J Oncol.* 2014;45:1531-1536.
- 103.** Makis W, Ciarallo A, Hickeson M, Derbekyan V, Novales-Diaz JA, Lisbona R. Gastric neuroendocrine carcinoma staged and followed with (18)F-FDG PET/CT--a report of 3 cases. *Clin Nucl Med.* 2013;38:447-450.
- 104.** Makis W, McCann K, McEwan AJ. Incidental Acinic Cell Carcinoma of the Parotid Gland Discordant on 123I-MIBG, 111In-Octreotide, and 18F-FDG PET/CT in a Patient With Neuroendocrine Tumor of the Cecum. *Clin Nucl Med.* 2015;40:676-678.
- 105.** Markou A, Manning P, Kaya B, Datta SN, Bomanji JB, Conway GS. [18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography imaging of thymic carcinoid tumor presenting with recurrent Cushing's syndrome. *Eur J Endocrinol.* 2005;152:521-525.
- 106.** Masi G, Fornaro L, Cupini S, et al. Refractory neuroendocrine tumor--response to liposomal doxorubicin and capecitabine. *Nat Rev Clin Oncol.* 2009;6:670-674.
- 107.** Mayerhoefer ME, Ba-Ssalamah A, Prosch H. [Oncologic imaging: indications for and limitations of modern cross-sectional imaging techniques]. *Radiologe.* 2013;53:313-321.
- 108.** Miederer M, Weber MM, Fottner C. Molecular imaging of gastroenteropancreatic neuroendocrine tumors. *Gastroenterol Clin North Am.* 2010;39:923-935.
- 109.** Minn H, Kauhanen S, Seppanen M, Nuutila P. 18F-FDOPA: a multiple-target molecule. *J Nucl Med.* 2009;50:1915-1918.
- 110.** Modlin IM, Drozdov I, Bodei L, Kidd M. Blood transcript analysis and metastatic recurrent small bowel carcinoid management. *BMC Cancer.* 2014;14:564.

- 111.** Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES. The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. *Am J Nucl Med Mol Imaging*. 2014;4:426-434.
- 112.** Munroe CA, Fehmi SM, Savides TJ. Endoscopic ultrasound in the diagnosis of pancreatic cancer. *Expert Opin Med Diagn*. 2013;7:25-35.
- 113.** Naji M, Hodolic M, El-Refai S, et al. Endocrine tumors: the evolving role of positron emission tomography in diagnosis and management. *J Endocrinol Invest*. 2010;33:54-60.
- 114.** Naswa N, Bal CS. Divergent role of (68)Ga-labeled somatostatin analogs in the workup of patients with NETs: AIIMS experience. *Recent Results Cancer Res*. 2013;194:321-351.
- 115.** Naswa N, Sharma P, Kumar A, et al. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. *AJR Am J Roentgenol*. 2011;197:1221-1228.
- 116.** Naswa N, Sharma P, Kumar A, et al. (6)(8)Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin. *Clin Nucl Med*. 2012;37:245-251.
- 117.** Nikolaou A, Thomas D, Kampanellou C, et al. The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center. *J Endocrinol Invest*. 2010;33:794-799.
- 118.** Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. *Hepatogastroenterology*. 2005;52:1259-1265.
- 119.** O'Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. *Eur J Surg Oncol*. 2008;34:324-332.
- 120.** Oberg K. Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs). *Theranostics*. 2012;2:448-458.
- 121.** Oh JR, Kulkarni H, Carreras C, Schalch G, Min JJ, Baum RP. Ga-68 Somatostatin Receptor PET/CT in von Hippel-Lindau Disease. *Nucl Med Mol Imaging*. 2012;46:129-133.
- 122.** Oh S, Prasad V, Lee DS, Baum RP. Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. *Int J Mol Imaging*. 2011;2011:524130.

- 123.** Orlefors H, Sundin A, Lu L, et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. *Eur J Nucl Med Mol Imaging*. 2006;33:60-65.
- 124.** Orsi F, Zhang L, Arnone P, et al. High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations. *AJR Am J Roentgenol*. 2010;195:W245-252.
- 125.** Ozkan ZG, Kuyumcu S, Uzum AK, et al. Comparison of (6)(8)Ga-DOTATATE PET-CT, (1)(8)F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. *Nucl Med Commun*. 2015;36:242-250.
- 126.** Pagou M, Zerizer I, Al-Nahhas A. Can gallium-68 compounds partly replace (18)F-FDG in PET molecular imaging? *Hell J Nucl Med*. 2009;12:102-105.
- 127.** Papadakis GZ, Millo C, Bagci U, Patronas NJ, Stratakis CA. Talc Pleurodesis With Intense 18F-FDG Activity But No 68Ga-DOTA-TATE Activity on PET/CT. *Clin Nucl Med*. 2015;40:819-820.
- 128.** Partelli S, Rinzivillo M, Maurizi A, et al. The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors. *Neuroendocrinology*. 2014;100:293-299.
- 129.** Pasquali C, Sperti C, Lunardi C, et al. [Positron emission tomography with fluorodeoxyglucose in gastro-entero-pancreatic tumors: diagnostic role and prognostic implications]. *Suppl Tumori*. 2005;4:S68-71.
- 130.** Pattison DA, Hofman MS. Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies. *PET Clin*. 2015;10:461-476.
- 131.** Paul D, Ostwal V, Bose S, Basu S, Gupta S. Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist's perspective. *Eur J Gastroenterol Hepatol*. 2016.
- 132.** Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. *Eur J Cancer*. 2003;39:1990-2005.
- 133.** Pfannenbergl AC, Aschoff P, Brechtel K, et al. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. *Br J Radiol*. 2007;80:437-445.
- 134.** Piccardo A, Lopci E, Conte M, et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. *Eur J Nucl Med Mol Imaging*. 2012;39:57-71.

- 135.** Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. *Eur J Nucl Med Mol Imaging*. 2010;37:67-77.
- 136.** Pruthi A, Pankaj P, Verma R, Jain A, Belho ES, Mahajan H. Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India. *J Gastrointest Oncol*. 2016;7:449-461.
- 137.** Putzer D, Gabriel M, Kendler D, et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. *Q J Nucl Med Mol Imaging*. 2010;54:68-75.
- 138.** Raue F, Frank-Raue K. Long-Term Follow-up in Medullary Thyroid Carcinoma. *Recent Results Cancer Res*. 2015;204:207-225.
- 139.** Riccabona G, Decristoforo C. Peptide targeted imaging of cancer. *Cancer Biother Radiopharm*. 2003;18:675-687.
- 140.** Ruf J, Heuck F, Schiefer J, et al. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. *Neuroendocrinology*. 2010;91:101-109.
- 141.** Sadowski SM, Millo C, Cottle-Delisle C, et al. Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. *J Am Coll Surg*. 2015;221:509-517.
- 142.** Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. *J Clin Oncol*. 2016;34:588-596.
- 143.** Sadowski SM, Weisbrod AB, Ellis R, et al. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions. *J Am Coll Surg*. 2014;218:997-1003.
- 144.** Salavati A, Prasad V, Schneider CP, Herbst R, Baum RP. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology. *Ann Nucl Med*. 2012;26:365-369.
- 145.** Scanga DR, Martin WH, Delbeke D. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. *Clin Nucl Med*. 2004;29:86-90.

- 146.** Schalin-Jantti C, Asa SL, Arola J, Sane T. Recurrent acute-onset Cushing's syndrome 6 years after removal of a thymic neuroendocrine carcinoma: from ectopic ACTH to CRH. *Endocr Pathol.* 2013;24:25-29.
- 147.** Scheidhauer K, Miederer M, Gaertner FC. [PET-CT for neuroendocrine tumors and nuclear medicine therapy options]. *Radiologe.* 2009;49:217-223.
- 148.** Schiesser M, Veit-Haibach P, Muller MK, et al. Value of combined 6-[<sup>18</sup>F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours. *Br J Surg.* 2010;97:691-697.
- 149.** Schmidt M, Eschner W, Dietlein M, Theissen P, Schicha H. [Established nuclear medicine techniques for tumour diagnosis (tumour SPECT): can they still compete with (<sup>18</sup>F)-FDG-PET?]. *Nuklearmedizin.* 2005;44:37-48; quiz N32-33.
- 150.** Schraml C, Schwenzer NF, Sperling O, et al. Staging of neuroendocrine tumours: comparison of [(6)(8)Ga]DOTATOC multiphase PET/CT and whole-body MRI. *Cancer Imaging.* 2013;13:63-72.
- 151.** Shamim SA, Kumar A, Kumar R. PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes. *PET Clin.* 2015;10:411-421.
- 152.** Shan L. 18F-Fluoroethyl triazole-betaAG-[(d)-Phe1-c(Cys2-Tyr3-(d)-Trp4-Lys5-Thr6-Cys7)Thr8]. *Molecular Imaging and Contrast Agent Database (MICAD).* Bethesda (MD); 2004.
- 153.** Shapiro B. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks. *Q J Nucl Med.* 1995;39:150-155.
- 154.** Sharma P, Mukherjee A, Bal C, Malhotra A, Kumar R. Somatostatin receptor-based PET/CT of intracranial tumors: a potential area of application for 68 Ga-DOTA peptides? *AJR Am J Roentgenol.* 2013;201:1340-1347.
- 155.** Sharma P, Singh H, Bal C, Kumar R. PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India. *Indian J Nucl Med.* 2014;29:2-12.
- 156.** Sharma P, Singh H, Basu S, Kumar R. Positron emission tomography-computed tomography in the management of lung cancer: An update. *South Asian J Cancer.* 2013;2:171-178.
- 157.** Shifrin AL, LiVolsi VA, Zheng M, et al. Neuroendocrine thymic carcinoma metastatic to the parathyroid gland that was reimplanted into the forearm in patient with multiple endocrine

neoplasia type 1 syndrome: a challenging management dilemma. *Endocr Pract.* 2013;19:e163-167.

**158.** Shin V, Bhargava P, Brown J, Ames ED, Kang P. Multimodality imaging features in a case of bronchial carcinoid including FDG PET. *Med Sci Monit.* 2007;13:CS4-8.

**159.** Singhal A, Singla S, Sharma P, Dhull VS, Khangembam BC, Kumar R. 68Ga DOTANOC PET/CT for accurate delineation of disease extent in a case of sinonasal small cell neuroendocrine carcinoma. *Clin Nucl Med.* 2013;38:e395-396.

**160.** Singla S, Gupta S, Reddy RM, Durgapal P, Bal CS. 68Ga-DOTA-NOC PET and peptide receptor radionuclide therapy in management of bilateral ovarian metastases from gastrointestinal carcinoid. *Jpn J Clin Oncol.* 2012;42:1202-1206.

**161.** Skoura E, Michopoulou S, Mohmaduvesh M, et al. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom. *J Nucl Med.* 2016;57:34-40.

**162.** Sollini M, Taralli S, Milella M, et al. Somatostatin receptor positron emission tomography/computed tomography imaging in Merkel cell carcinoma. *J Eur Acad Dermatol Venereol.* 2015.

**163.** Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. *J Nucl Med.* 2010;51:875-882.

**164.** Srirajaskanthan R, Toubanakis C, Dusmet M, Caplin ME. A review of thymic tumours. *Lung Cancer.* 2008;60:4-13.

**165.** Stamatis G. Neuroendocrine tumors of the lung: the role of surgery in small cell lung cancer. *Thorac Surg Clin.* 2014;24:313-326.

**166.** Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. *Best Pract Res Clin Endocrinol Metab.* 2007;21:69-85.

**167.** Swanson MS, Sinha UK. Diagnosis and management of merkel cell carcinoma of the head and neck: current trends and controversies. *Cancers (Basel).* 2014;6:1256-1266.

**168.** Szymanowski B, Duchnowska R, Bilski M, et al. Problems of diagnostic assessment in advanced pancreatic neuroendocrine neoplasm and treatment implications: a case report and literature review. *Nucl Med Rev Cent East Eur.* 2016;19:54-57.

**169.** Tabaksblat EM, Langer SW, Knigge U, et al. Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art. *Acta Oncol.* 2016;55:3-14.

- 170.** Talbot JN, Kerrou K, Missoum F, et al. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetretotide-(111In) SPECT data. *Mol Imaging Biol.* 2005;7:257-261.
- 171.** Tan TH, Lee BN, Hassan SZ. Diagnostic Value of (68)Ga-DOTATATE PET/CT in Liver Metastases of Neuroendocrine Tumours of Unknown Origin. *Nucl Med Mol Imaging.* 2014;48:212-215.
- 172.** Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. *Front Neuroendocrinol.* 2013;34:228-252.
- 173.** Tirumani SH, Shinagare AB, Sakellis C, et al. Merkel cell carcinoma: a primer for the radiologist. *AJR Am J Roentgenol.* 2013;200:1186-1196.
- 174.** Tran K, Khan S, Taghizadehasl M, et al. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. *Hell J Nucl Med.* 2015;18:19-24.
- 175.** Treglia G, Castaldi P, Villani MF, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. *Eur J Nucl Med Mol Imaging.* 2012;39:569-580.
- 176.** Treglia G, Villani MF, Giordano A, Rufini V. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. *Endocrine.* 2012;42:535-545.
- 177.** Tseng CH, Huang WS, Muo CH, Chang YJ, Kao CH. Increased depression risk among patients with chronic osteomyelitis. *J Psychosom Res.* 2014;77:535-540.
- 178.** Upadhyay B, Lu SJ, Navalkissoor S, Gnanasegaran G, Buscombe J. The imaging of neuroendocrine tumors using single photon emission computed tomography/computed tomography. *Q J Nucl Med Mol Imaging.* 2015;59:140-151.
- 179.** van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ. Neuroendocrine tumours: the role of imaging for diagnosis and therapy. *Nat Rev Endocrinol.* 2014;10:102-114.
- 180.** Velikyan I, Sundin A, Eriksson B, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. *Nucl Med Biol.* 2010;37:265-275.

- 181.** Venkitaraman B, Karunanithi S, Kumar A, Bal C, Ammini AC, Kumar R. (6)(8)Ga-DOTATOC PET-CT in the localization of source of ectopic ACTH in patients with ectopic ACTH-dependent Cushing's syndrome. *Clin Imaging*. 2014;38:208-211.
- 182.** Virgolini I, Gabriel M, Kroiss A, et al. Current knowledge on the sensitivity of the 68Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 2016.
- 183.** Wang L, Tang K, Zhang Q, et al. Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors. *Biomed Res Int*. 2013;2013:102819.
- 184.** Werner MK, Aschoff P, Reimold M, Pfannenbergl C. FDG-PET/CT-guided biopsy of bone metastases sets a new course in patient management after extensive imaging and multiple futile biopsies. *Br J Radiol*. 2011;84:e65-67.
- 185.** Willhauck MJ, Popperl G, Rachinger W, Giese A, Auernhammer CJ, Spitzweg C. An unusual case of ectopic ACTH syndrome. *Exp Clin Endocrinol Diabetes*. 2012;120:63-67.
- 186.** Xu C, Zhang H. Somatostatin receptor based imaging and radionuclide therapy. *Biomed Res Int*. 2015;2015:917968.
- 187.** Yakemchuk VN, Jager PL, Chirakal R, Reid R, Major P, Gulenchyn KY. PET/CT using (1)(8)F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting. *Nucl Med Commun*. 2012;33:322-330.
- 188.** Yao J, Gan G, Farlow D, et al. Impact of F18-fluorodeoxyglucose positron emission tomography/computed tomography on the management of resectable pancreatic tumours. *ANZ J Surg*. 2012;82:140-144.
- 189.** Yao M, Smith RB, Hoffman HT, Funk GF, Graham MM, Buatti JM. Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance. *Am J Clin Oncol*. 2005;28:205-210.
- 190.** Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. *Cancer*. 2005;104:2292-2309.